, but can still influence Earth's ionosphere. By contrast, neutron stars that accrete matter from a companion star can produce 'type-I' X-ray bursts, resulting from runaway thermonuclear combustion of matter accumulated on the neutron star's surface. These bursts repeat, but they cannot explain the observed signals because they last for only a few minutes and are less luminous by a factor of about 100 (ref. 5) . Finally, neutron stars can also exhibit super-bursts, which are longer versions of type-I X-ray bursts (lasting for a few hours 6 ), but these are also under-luminous compared with the flares discovered here. Therefore, even within this zoo of different transient phenomena, Irwin and colleagues' flaring sources remain unmatched.
Do we have any other information? Both sources are located in old stellar populations, which probably rules out the presence of young neutron stars such as magnetars. In addition, the sources reside in what seem to be globular clusters or ultracompact dwarf galaxies. The optical spectrum from one of the sources shows that it is at the same distance from Earth as is its host galaxy, which confirms that we are not looking at a star in the Milky Way that is being projected onto a more distant galaxy. Both sources also have a high X-ray luminosity before and after their flares that is larger than can be achieved by a neutron star (even if exceptions exist for young neutron stars 7 ). All of these observations seem to suggest the presence of a black hole.
If the black-hole interpretation is correct, there are at least two viable explanations. One possibility, which is suggested by the authors, is that there exists an intermediate-mass black hole (100-1,000 times the mass of the Sun) at the centre of each source that, for some unknown reason, emits flares that last for about an hour. Alternatively, one could envisage a lower-mass black hole whose X-ray emissions are beamed directly towards Earth. A binary system that has a highly eccentric orbit 8 might explain the repeated flares detected from the source near NGC 5128). The flares from such a binary system would be strictly periodic, because sporadic surges of accretion would occur at the point of closest approach.
The mystery of Irwin and collaborators' flares might be solved, as often happens in astrophysics, with more observations. In particular, one could investigate the frequency at which the flares occur. An important aspect of the authors' discovery is that both sources were identified after a careful search through archival data, which provides further testimony for the legacy value of such archives. Now that we know these strange objects are out there, they will remain on the watch list and more examples will be searched for. ■ 
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T umour cells are subject to various forms of stress, such as oxygen or nutrient shortages, when tumour blood-vessel formation cannot keep pace with tumour growth -and the cells therefore need to have effective stress-survival strategies. Heat-shock proteins (HSPs) are often active in cells exposed to stressful conditions. On page 397, Rodina et al. 1 have investigated the role of HSPs in human cancer, and find that the proteins exist in a large complex in some cancer cells.
Maintenance of the correct 3D structure of a protein is essential for its function, and cells have mechanisms dedicated to protein quality control. Proteins with structural defects are either refolded into the correct conformation or, in the case of severe structural abnormality, targeted for degradation. Protein quality control is regulated by chaperone proteins, which are often involved in facilitating folding. Chaperones include HSPs, which are active in human cells both under normal conditions and in stressful conditions such as inflammation and a state of reduced oxygen known as hypoxia.
Rodina and colleagues investigated HSPs in human cancer cells using a biochemical technique that separates proteins in samples of cellular proteins. The authors found that, in samples of what they call 'type 2' cancer cells, the heat-shock protein HSP90 separated as expected on the basis of its structure. However, in other samples tested, HSP90 had an unexpected separation pattern that could be explained by its presence in a large complex with other HSPs. The authors use the term 'type 1' cancer cells to describe cells containing this large protein complex (Fig. 1) .
The researchers found that, in type 1 cancer cells, HSP90 associated with dozens of other proteins, including scaffolding and adaptor proteins, which are also involved in regulating protein folding. The authors called this structure the epichaperome. By contrast, in type 2 cancer cells and non-cancer cells, HSP90 was associated with only a small set of proteins, and most of the HSPs existed as solitary proteins or were assembled into small complexes.
HSP90 requires the essential nucleotide ATP to function. The authors therefore targeted the epichaperome using the molecule PU-H71, which binds to HSP90's ATP-binding pocket and inhibits the protein's function. The inhibitor bound more tightly when HSP90 was in the epichaperome, and killed more type 1 cancer cells than type 2 or non-cancer cells. This difference was not attributable solely to chemical inactivation of HSP90, because the authors
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Chemical diversity targets malaria
A molecule selected from a library of compounds that have structures similar to natural products targets several stages of the malarial parasite's life cycle, offering single-dose treatment of the disease in mouse models. See Article p.344
liminating malaria would save more than 400,000 lives annually, mainly those of young children in sub-Saharan Africa, and prevent the approximately 200 million cases of the disease that arise each year 1 . Achieving this will require medicines that can eliminate all three stages of Plasmodium parasite infection in humans. On page 344, Kato et al. 2 report compounds, known as bi cyclic azetidines, that display this multistage activity.
Kato and colleagues' work comes at a pivotal time. Malaria treatments rely on artemisininbased combination therapies (ACTs), which combine an artemisinin-based compound with a second antimalarial drug. The rapid efficacy and global implementation of ACTs, coupled with increased mosquito-vector control efforts, have halved malaria death rates in the past 15 years 1 . However, artemisinin resistance has emerged and is now widespread in southeast Asia 3 . This places the partner drugs under increased evolutionary selection pressure for the development of resistance. In found that selective genetic down regulation of other HSPs resulted in increased death of type 1 cells compared with type 2 cells, suggesting that type 1 cell survival depends on an intact epichaperome.
Using protein-complex analysis techniques and PU-H71 treatment, Rodina and colleagues investigated the epichaperome in different types of cancer cell. The epichaperome was detected in 60-70% of cell lines from breast, pancreatic, lung, leukaemia and other cancers, indicating the potential clinical relevance of this protein complex as a therapeutic target. Strikingly, the epichaperome was not restricted to a particular cancer subset characterized by specific gene or protein expression. Type 1 cells also had high levels of the cancer-associated MYC protein. When MYC was down regulated, the epichaperome disappeared, whereas overexpressing MYC in type 2 cells induced epichaperome formation. Thus, MYC is an important regulator of epichaperome assembly.
Treatments for cancer require a target that is present in most cancer cells but absent in normal cells. Rodina and colleagues' finding that type 1 cancer cells contain HSP90 in the epichaperome, but that normal cells have HSP90 mainly in a non-complexed form, suggests that the epichaperome might be a clinical target.
Despite the encouraging results, the authors found considerable differences in dependence on epichaperome formation, both between tumour types and between tumour cells of the same type (for example, breast cancer), which might allow the emergence of treatment-resistant variants. Moreover, in many cancers, such as breast cancer, the metastatic migration of cancer cells to other locations in the body is the main cause of death, and metastatic cells may differ from the initial primary tumours. It remains to be determined to what extent metastatic cells depend on epichaperome formation, and how such cells might respond to drugs that target the complex.
However, obtaining metastatic tissue from a patient by needle biopsy is a problem because of the procedure's invasive nature, and some lesions (for example, in the lung, bone and brain) are difficult to access. 'Liquid biopsy' of circulating tumour cells in the peripheral blood might be an alternative feasible strategy for assessing the epichaperome in metastatic cells. Analysis of circulating tumour cells or tumour cells that have migrated to the bone marrow in people in the early stages of cancer might also provide information on potential precursors of metastases 2, 3 . Rodina and colleagues' findings could have broader implications. Many cellular programs consist of signalling pathways that rely on a large number of proteins, and these might form stable complexes in a similar way to how the epichaperome forms. For example, the chaperone machinery in a cellular organelle 
